PTC Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PTC Therapeutics, Inc.
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
PTC Therapeutics is one of many companies in the life sciences sector whose regulatory targets have been adversely affected by the coronavirus pandemic.
A number of advanced therapies are likely to be approved in the EU this year.
- Antisense, Oligonucleotides
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Agilis Biotherapeutics, Inc.
- Censa Pharmaceuticals Inc.